BRAIN CANCER

Vorasidenib shows significant long-term benefits for IDH-mutant glioma patients, enhancing survival and delaying treatment needs post-surgery.

Exosome-based therapy for glioblastoma receives FDA orphan drug designation, promising targeted treatment and improved delivery methods for cancer care.

The FDA fast tracks MT-125, a promising new treatment for glioblastoma, enhancing patient care and expediting drug development.

A clinical study highlights the safety and feasibility of ClearPoint Prism Neuro Laser Therapy for treating brain tumors, showcasing innovative minimally invasive techniques.

FDA grants orphan drug designation to cintredekin besudotox, offering new hope for glioblastoma treatment with targeted delivery methods.

FDA designates AMXT 1501 and DFMO as an orphan drug for neuroblastoma, aiming to enhance treatment outcomes for pediatric patients.

Dordaviprone gains NCCN approval as a promising treatment for recurrent H3 K27M-mutant diffuse glioma, addressing urgent patient needs.

The FDA approves selumetinib for young patients with neurofibromatosis type 1, offering hope for effective treatment of inoperable tumors.

FDA grants orphan drug designation to BA-101, a promising treatment for glioblastoma, aiming to improve outcomes in this challenging cancer.

Lantern Pharma advances pediatric CNS cancer treatment with FDA guidance on LP-184 trial, targeting rare tumors and enhancing therapy with spironolactone.

Dr Patrick Wen discusses the FDA approval of dordaviprone, highlighting its potential to improve outcomes for patients with challenging brain tumors.

In a pilot study, a novel regimen showed 100% disease control in 5 patients with recurrent GBM, with 2 achieving near complete response.

Dordaviprone received accelerated FDA approval for H3 K27M-mutant diffuse midline glioma, an aggressive brain tumor, making it the first approved systemic therapy for this rare disease.

A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this aggressive brain cancer.

FDA accelerates approval of dordaviprone, the first targeted therapy for aggressive diffuse midline glioma, offering hope for patients with H3 K27M mutation.

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor cells.

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, offering hope for patients with limited options.

Researchers explore glioblastoma's genetic complexity using innovative spatial profiling, aiming to enhance treatment strategies and understand tumor resistance.

A study strongly supports stereotactic radiation for up to 20 brain metastases, proving superior to even advanced whole-brain techniques and widely accessible.

The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing difficulties.

Ayal Aizer, MD, MHS, discusses the findings of a phase 3 study investigating the use of stereotactic radiation vs whole-brain radiation in patients with 5 to 20 brain metastases.

FDA designates MB-101 CAR T-cell therapy for glioblastoma, highlighting its potential in treating aggressive brain tumors with innovative combination strategies.

A new trial optimizes rhenium Re 186 obisbemeda dosing for treating leptomeningeal metastases, aiming to enhance safety and efficacy in CNS cancer therapy.

The SonoClear System revolutionizes neurosurgery with FDA breakthrough designation, enhancing ultrasound imaging for safer tumor resections in glioma surgeries.

Myrio's PHOX2B PC-CAR T therapy gains FDA approval for human trials, promising innovative treatment for patients with high-risk neuroblastoma.